Rachel Anderson
Nurse Practitioner · Charlottesville, VANPI 1225383656
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,229 of the $89,862 with a category attached, or 91.5%. AbbVie accounts for 97.3% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $39,502, more than ten times the $737 reported in 2021. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $401.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$87K
- UCB, Inc.$420
- Idorsia Pharmaceuticals US Inc$329
- Novartis$265
- Biohaven Pharmaceuticals, Inc.$257
- Paragonix Technologies, Inc.$160
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$82,22992%
- Travel & lodging$3,4604%
- Food & beverage$4,0745%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $87,397 |
| UCB, Inc. | 19 | $420 |
| Idorsia Pharmaceuticals US Inc | 7 | $329 |
| Novartis | 14 | $265 |
| Biohaven Pharmaceuticals, Inc. | 7 | $257 |
| Paragonix Technologies, Inc. | 3 | $160 |
| TG Therapeutics, Inc. | 5 | $118 |
| Neurocrine Biosciences, Inc. | 6 | $113 |
| CSL Behring | 1 | $100 |
| Biogen | 4 | $89 |
| Neurelis, Inc. | 4 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Lundbeck LLC | 3 | $69 |
| Lilly USA, LLC | 3 | $56 |
| Pfizer | 3 | $50 |
| Genentech USA, Inc. | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Kyowa Kirin, Inc. | 2 | $31 |
| Edwards Lifesciences | 1 | $28 |
| Johnson & Johnson | 2 | $26 |
| Eisai Inc. | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $16 |
| Bayer | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$63,782
- UBRELVY$47,029
- QUVIVIQ$235
- NURTEC ODT$125
- Kcentra$100
How this compares
$89,862 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 14 | $412 |
| Azithromycin | 15 | $204 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $43 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Charlottesville
- Mikel GrayCharlottesville$174K
- Terran SimsCharlottesville$10K
- Amy McDonnellCharlottesville$7K
- Samantha FoxGate City$207K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
- Megan FrancisArlington$81K
- Elizabeth WilletteNorfolk$58K
- Lacey LyleSuffolk$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.